MoonLake ImmunotherapeuticsMLTXNASDAQ
Loading
Operating Cash Flow Growth Under PressureDecelerating
Percentile Rank45
Studio
Year-over-Year Change

Year-over-year operating cash flow growth rate

Latest
-31.99%
↑ 98% vs avg
Percentile
P45
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
-1598.56%
Historical baseline
PeriodValue
Q4 2025-31.99%
Q3 202518.31%
Q2 2025-42.97%
Q1 202521.32%
Q4 2024-91.78%
Q3 20249.37%
Q2 2024-86.58%
Q1 2024-21.09%
Q4 2023-33.44%
Q3 202323.92%
Q2 2023-34.73%
Q1 202322.18%
Q4 2022-24.00%
Q3 202272.62%
Q2 2022-140.75%
Q1 2022-90.36%
Q4 2021-269.17%
Q3 2021-32976.30%
Q2 2021105.70%
Q1 20210.00%
Q4 20200.00%